iomx therapeutics ag logo

iOmx Therapeutics AG

iOmx Therapeutics is a start-up biotech company in the immuno-oncology field. We are focused on innovation-driven research to advance our proprietary early stage novel immune-checkpoint molecules through pre-clinical and clinical development.

iOmx was founded based on work from the laboratory of oncology expert and co-founder Philipp Beckhove, previously at the German Cancer Research Center, Heidelberg, and now at the RCI Regensburg Center for Interventional Immunology.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://iomx.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Fraunhoferstrasse 1382152 4th Floor
Martinsried/ Munich
Germany
Email
Contact Number
+49 89 899970900

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/iomx-therapeutics” connections=”true” suffix=””]

IOmxs founders have developed a high-throughput siRNA-based screening approach that allows a comprehensive identification of ligands on human cancer cells that inhibit CTL-mediated tumor cell killing. To date, this screening technology has been applied to tumor cells derived from breast cancer, pancreatic cancer,melanoma and multiple myeloma. More than twenty novel targets have been identified which form the basis of the companys pre-clinical product portfolio.

In Sep 2016, iOmx secured EUR 40 Mn in Series A financing round. MPM Capital and Sofinnova Partners co-led the round, and were joined by Wellington Partners and Merck Ventures.